Absci (ABSI) EBIT (2020 - 2026)
Absci (ABSI) posted EBIT of -$30.8 million for Q1 2026, up 0.63% sequentially from -$31.0 million in Q4 2025, and down 11.24% YoY from -$34.8 million in Q1 2025.
Absci (ABSI) EBIT (2020 - 2026) Analysis & Trends
Absci has reported EBIT for 7 years, with the latest figure at -$30.8 million in Q1 2026.
- Quarterly EBIT fell 11.24% year-over-year to -$30.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$123.4 million (down 9.12% YoY) and the FY2025 annual result came in at -$120.3 million, down 10.5% from the prior year.
- EBIT grew to -$30.8 million in Q1 2026 per ABSI's latest filing, from -$31.0 million in the prior quarter.
- Over five years, EBIT peaked at -$21.1 million in Q4 2022 and troughed at -$43.0 million in Q2 2023.
- A 5-year average of -$28.4 million and a median of -$28.8 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2024: EBIT tumbled 158.37% in 2022, then surged 37.84% in 2024.
- Over 5 years, EBIT stood at -$21.1 million in 2022, then decreased by 17.29% to -$24.7 million in 2023, then retreated by 20.35% to -$29.8 million in 2024, then declined by 4.26% to -$31.0 million in 2025, then grew by 0.63% to -$30.8 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$30.8 million, -$31.0 million, and -$30.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | -34.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.16 Mn |
| Mar 31, 2026 | -30.85 Mn |
| Dec 31, 2025 | -31.04 Mn |
| Sep 30, 2025 | -30.15 Mn |
| Jun 30, 2025 | -31.39 Mn |
| Mar 31, 2025 | -27.73 Mn |
| Dec 31, 2024 | -29.77 Mn |
| Sep 30, 2024 | -28.90 Mn |
| Jun 30, 2024 | -26.72 Mn |
| Mar 31, 2024 | -23.50 Mn |
| Dec 31, 2023 | -24.74 Mn |
| Sep 30, 2023 | -23.30 Mn |
| Jun 30, 2023 | -42.99 Mn |
| Mar 31, 2023 | -24.49 Mn |
| Dec 31, 2022 | -21.09 Mn |
| Sep 30, 2022 | -27.97 Mn |
| Jun 30, 2022 | -28.89 Mn |
| Mar 31, 2022 | -28.80 Mn |
| Dec 31, 2021 | -26.26 Mn |
| Sep 30, 2021 | -21.14 Mn |